<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993824</url>
  </required_header>
  <id_info>
    <org_study_id>03901-09-C</org_study_id>
    <nct_id>NCT00993824</nct_id>
  </id_info>
  <brief_title>Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes</brief_title>
  <official_title>Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Diabetes Center at Park Nicollet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain continuous glucose monitoring (CGM) data from
      individuals taking Welchol compared to placebo. The CGM data will determine the effect on
      glucose control of adding Welchol to an anti-diabetic medication regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To understand the effect of the addition of colesevelam HCl to oral agent therapy in
      individuals with type 2 diabetes on glycemic control by utilizing a novel technology,
      continuous glucose monitoring with ambulatory glucose profile analysis. To date there are no
      studies of this compound that have employed continuous glucose monitoring (CGM) with
      ambulatory glucose profile (AGP) analysis to obtain data that will detail the diurnal glucose
      patterns associated with this therapy. We plan to employ CGM at critical points throughout
      the study. AGP analysis will enable rapid assessment of the clinical status of the subject.
      Using statistically stable estimates of hourly values represented by five percentile curves
      AGP depicts glucose exposure, variability and stability. Previously, we have used AGP
      analysis to characterize glucose perturbations in individuals ranging from normal glucose
      tolerance to overt type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Norm AUC Average by Group (Normalized)</measure>
    <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
    <description>Double Blinded CGM used for 2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Norm AUC Average by Group (Normalized)</measure>
    <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
    <description>Overnight glucose captured by CGM.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wake Norm AUC Average by Group (Normalized)</measure>
    <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
    <description>Wake glucose captured by continuous glucose monitoring (CGM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemia Percentage of Time &lt;70 mg/dL Average by Group</measure>
    <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
    <description>Ambulatory glucose profile (AGP) reports were examined for the changes in the incidence of hypoglycemia (CGM&lt;70 mg/dL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Welchol then Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Welchol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colesevelam HCl</intervention_name>
    <description>3.75 grams of colesevelam HCl (6 tablets)</description>
    <arm_group_label>Welchol then Placebo</arm_group_label>
    <arm_group_label>Placebo then Welchol</arm_group_label>
    <other_name>Welchol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Welchol then Placebo</arm_group_label>
    <arm_group_label>Placebo then Welchol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥18 and ≤75 years of age

          -  Clinical diagnosis of type 2 diabetes

          -  Currently treated with metformin, a sulfonylurea, or combination
             metformin/sulfonylurea; stable dose for ≥3 months

          -  HbA1c of 7.0-9.0% inclusive

          -  If taking lipid lowering medications, stable dose for &gt;30 days

        Exclusion Criteria:

          -  Taken oral or injected prednisone or cortisone medications in the previous 30 days.
             (Topical or inhaled steroids will not be considered excluded medications.)

          -  Current use of insulin or TZD's, or incretins

          -  LDL &lt;70 mg/dL

          -  Serum triglycerides &gt;500 mg/dL

          -  History of hypertriglyceridemia-induced pancreatitis

          -  History of gastrointestinal disorder such as dysphagia, swallowing disorder,
             intestinal motility disorder or prior bowel obstruction

          -  History or presence of any severe medical or psychological condition or chronic
             conditions/infections that in the opinion of the Investigator would compromise the
             subject's safety or successful participation in the study

          -  Unable to follow the study protocol

          -  Unable to speak, read and write in English

          -  Pregnant, planning to become pregnant, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger S. Mazze, PhD</last_name>
    <role>Study Director</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elinor S. Strock, APRN, BC</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M. Cuddihy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.</citation>
    <PMID>18852398</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, Cuddihy R. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008 Jun;10(3):149-59. doi: 10.1089/dia.2007.0293.</citation>
    <PMID>18473688</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531.</citation>
    <PMID>18663165</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazze RS, Strock E, Borgman S, Wesley D, Stout P, Racchini J. Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring (CGM): Is CGM ready for real time? Diabetes Technol Ther. 2009 Jan;11(1):11-8. doi: 10.1089/dia.2008.0041.</citation>
    <PMID>19132850</PMID>
  </results_reference>
  <results_reference>
    <citation>Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007 Jan;29(1):74-83.</citation>
    <PMID>17379048</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <results_first_submitted>September 5, 2013</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Jan 2010 to Mar 2011. Medical Clinic Setting.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Welchol Then Placebo</title>
          <description>3.75 grams of colesevelam HCl (Welchol) taken for 12 weeks at evening meal, and then crossover to placebo taken at evening meal fro 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Welchol</title>
          <description>Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Welchol Then Placebo</title>
          <description>3.75 grams of colesevelam HCl taken at evening meal for 12 weeks, then crossover to placebo taken at evening meal for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Welchol</title>
          <description>Placebo taken at evening meal for 12 weeks, then crossover to 3.75 grams of colesevelam HCl taken at evening meal for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.5" spread="9.4"/>
                    <measurement group_id="B2" value="59.5" spread="7.2"/>
                    <measurement group_id="B3" value="59.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total norm AUC average</title>
          <description>Total norm HbA1c AUC was assessed by the CGM. The baseline CGM period started 14 days before randomization (visit 1) and concluded at randomization (visit 2). The data was then normalized.</description>
          <units>mg/(dL/hr) (normalized)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.2" spread="16.0"/>
                    <measurement group_id="B2" value="167.7" spread="25.9"/>
                    <measurement group_id="B3" value="164.8" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleep norm Area under the curve average by group</title>
          <description>Sleep norm HbA1c AUC was assessed by the CGM. The baseline CGM period started 14 days before randomization (visit 1) and concluded at randomization (visit 2). The data was then normalized.</description>
          <units>mg/(dL/hr) (normalized)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.1" spread="14.3"/>
                    <measurement group_id="B2" value="161.2" spread="23.4"/>
                    <measurement group_id="B3" value="159.1" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wake norm area under the curve average by group</title>
          <description>Wake norm HbA1c AUC was assessed by the CGM. The baseline CGM period started 14 days before randomization (visit 1) and concluded at randomization (visit 2). The data was then normalized.</description>
          <units>mg/(dL/hr) (normalized)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.2" spread="17.8"/>
                    <measurement group_id="B2" value="170.0" spread="28.1"/>
                    <measurement group_id="B3" value="167.5" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypoglycemia percentage of time &lt;70 mg/dL average by group</title>
          <description>Hypoglycemia percentage of time &lt;70 mg/dL average by group was assessed by the CGM. The baseline CGM period started 14 days before randomization (visit 1) and concluded at randomization (visit 2).</description>
          <units>percentage of time &lt;70 mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.4" spread="0.4"/>
                    <measurement group_id="B2" value="0.3" spread="0.6"/>
                    <measurement group_id="B3" value="0.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Norm AUC Average by Group (Normalized)</title>
        <description>Double Blinded CGM used for 2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</description>
        <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Welchol Then Placebo</title>
            <description>3.75 grams of colesevelam HCl taken at evening meal for 12 weeks, then crossover to placebo taken at evening meal for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Welchol</title>
            <description>Placebo taken at evening meal for 12 weeks, then crossover to 3.75 grams of colesevelam HCl taken at evening meal for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Norm AUC Average by Group (Normalized)</title>
          <description>Double Blinded CGM used for 2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</description>
          <units>mg/(dL/hr) normalized</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.8" spread="10.8"/>
                    <measurement group_id="O2" value="175.9" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.9" spread="17.2"/>
                    <measurement group_id="O2" value="175.1" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.2" spread="23.5"/>
                    <measurement group_id="O2" value="159.4" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.9" spread="33.2"/>
                    <measurement group_id="O2" value="159.4" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Norm AUC Average by Group (Normalized)</title>
        <description>Overnight glucose captured by CGM.</description>
        <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Welchol Then Placebo</title>
            <description>3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
colesevelam HCl: 3.75 grams of colesevelam HCl (6 tablets)
placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Welchol</title>
            <description>Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
colesevelam HCl: 3.75 grams of colesevelam HCl (6 tablets)
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Norm AUC Average by Group (Normalized)</title>
          <description>Overnight glucose captured by CGM.</description>
          <units>mg/(dL/hr) normalized</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.4" spread="16.6"/>
                    <measurement group_id="O2" value="161.9" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.0" spread="24.0"/>
                    <measurement group_id="O2" value="160.2" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.8" spread="31.8"/>
                    <measurement group_id="O2" value="147.9" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.0" spread="32.5"/>
                    <measurement group_id="O2" value="143.6" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Wake Norm AUC Average by Group (Normalized)</title>
        <description>Wake glucose captured by continuous glucose monitoring (CGM).</description>
        <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Welchol Then Placebo</title>
            <description>3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
colesevelam HCl: 3.75 grams of colesevelam HCl (6 tablets)
placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Welchol</title>
            <description>Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
colesevelam HCl: 3.75 grams of colesevelam HCl (6 tablets)
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Wake Norm AUC Average by Group (Normalized)</title>
          <description>Wake glucose captured by continuous glucose monitoring (CGM).</description>
          <units>mg/(dL/hr) (normalized)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.3" spread="11.7"/>
                    <measurement group_id="O2" value="180.9" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.2" spread="16.0"/>
                    <measurement group_id="O2" value="180.6" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.2" spread="21.2"/>
                    <measurement group_id="O2" value="163.8" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.9" spread="34.2"/>
                    <measurement group_id="O2" value="165.2" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hypoglycemia Percentage of Time &lt;70 mg/dL Average by Group</title>
        <description>Ambulatory glucose profile (AGP) reports were examined for the changes in the incidence of hypoglycemia (CGM&lt;70 mg/dL)</description>
        <time_frame>2 week periods at the start of treatment 1, end of treatment 1, start of treatment 2, and end of treatment 2.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Welchol Then Placebo</title>
            <description>3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
colesevelam HCl: 3.75 grams of colesevelam HCl (6 tablets)
placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Welchol</title>
            <description>Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
colesevelam HCl: 3.75 grams of colesevelam HCl (6 tablets)
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Percentage of Time &lt;70 mg/dL Average by Group</title>
          <description>Ambulatory glucose profile (AGP) reports were examined for the changes in the incidence of hypoglycemia (CGM&lt;70 mg/dL)</description>
          <units>percentage of time &lt;70 mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.1"/>
                    <measurement group_id="O2" value="0.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.2"/>
                    <measurement group_id="O2" value="0.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.2"/>
                    <measurement group_id="O2" value="0.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Welchol</title>
          <description>3.75 grams of colesevelam HCl taken at evening meal</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo taken at evening meal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roger Mazze PhD</name_or_title>
      <organization>International Diabetes Center</organization>
      <phone>952-993-3796</phone>
      <email>rmazze@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

